Associate Professor Jagat Kanwar is an immunologist and molecular biochemist. He is group leader of the Laboratory of Immunology and Molecular Biomedical Research has an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic infl ammation. He is an immunologist, molecular biologist and cell biologist. He has extensive training and expertise in studying the molecular mechanisms and devising treatments for human diseases like cancer and chronic infl ammatory diseases such as asthma, atherosclerosis, infl ammatory bowel disease (IBD), arthritis and multiple sclerosis in both in vivo and in vitro models. The research approach employed monotherapy (gene therapy, immunotherapy) or combinational therapy with commercially available chemotherapeutic agents including peptides. From 2002- 2006, within Lactopharma his main research project involved the identifi cation of milk bioactive molecules/ fractions for the treatment of cancer and employed monotherapy (gene therapy, immunotherapy or antiangiogenic molecules) or combinational therapy with milk and natural plant bioactives and the results obtained have generated 3 patents and two provisional are to be submitted. He is working on nanotechnology based peptide, siRNA and miRNA delivery for targeting survivin (currently most attractive cancer target), HIF-1α and apoptotic cell signalling molecules expression in the cancers and infl ammations. For commercial funded grants his research group carries out research in the areas of dairy/grain bioactives as immunomodulators, their role in bone and muscle development, osteoarthritis and wound healing. Presently his 7 PhD students are working on various cancer biomarkers and nanobiotechnological oral delivery systems for gene transfer technology and proteins in cancers. For commercial funded grants his research group carries out research in the areas of bioactives as immunomodulators, their role in bone, muscle development and osteoarthritis. His publications have added to the body of knowledge in the fi elds of nanobiotechnology, cancer gene therapy, cell biology and immunology. Kanwar’s research work generated in total of 12 patent/PCTs with two provisionals in preparation. Five of these patents have been licensed for commercialization to biotech companies Antisoma, NeuronZ, Neuren Pharmaceuticals and Fonterra. He was invited as a speaker in more than 30 conferences and chaired sessions in Immunology, Nanotechnology, Nanomedicine and Biotechnology Associate Professor Jagat Kanwar is an immunologist and molecular biochemist. He is group leader of the Laboratory of Immunology and Molecular Biomedical Research has an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic infl ammation. He is an immunologist, molecular biologist and cell biologist. He has extensive training and expertise in studying the molecular mechanisms and devising treatments for human diseases like cancer and chronic infl ammatory diseases such as asthma, atherosclerosis, infl ammatory bowel disease (IBD), arthritis and multiple sclerosis in both in vivo and in vitro models. The research approach employed monotherapy (gene therapy, immunotherapy) or combinational therapy with commercially available chemotherapeutic agents including peptides. From 2002- 2006, within Lactopharma his main research project involved the identifi cation of milk bioactive molecules/ fractions for the treatment of cancer and employed monotherapy (gene therapy, immunotherapy or antiangiogenic molecules) or combinational therapy with milk and natural plant bioactives and the results obtained have generated 3 patents and two provisional are to be submitted. He is working on nanotechnology based peptide, siRNA and miRNA delivery for targeting survivin (currently most attractive cancer target), HIF-1α and apoptotic cell signalling molecules expression in the cancers and infl ammations. For commercial funded grants his research group carries out research in the areas of dairy/grain bioactives as immunomodulators, their role in bone and muscle development, osteoarthritis and wound healing. Presently his 7 PhD students are working on various cancer biomarkers and nanobiotechnological oral delivery systems for gene transfer technology and proteins in cancers. For commercial funded grants his research group carries out research in the areas of bioactives as immunomodulators, their role in bone, muscle development and osteoarthritis. His publications have added to the body of knowledge in the fi elds of nanobiotechnology, cancer gene therapy, cell biology and immunology. Kanwar’s research work generated in total of 12 patent/PCTs with two provisionals in preparation. Five of these patents have been licensed for commercialization to biotech companies Antisoma, NeuronZ, Neuren Pharmaceuticals and Fonterra. He was invited as a speaker in more than 30 conferences and chaired sessions in Immunology, Nanotechnology, Nanomedicine and Biotechnology

Biomarker